Study summary · research use only
Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This double-blind randomized trial in 21 Indonesian female human subjects aged 26 to 55 years compared Acetylhexapeptide-3 (AHP-3) cream, Palmitoyl pentapeptide-4 (PPP-4) cream, and a placebo, applied twice daily to the periorbital area for eight weeks, for effects on crow's feet skin aging. Outcomes were assessed with Corneometer, Tewameter, Cutometer, digital photography, and the Crow's Feet Grading Scale. Based on clinical photos and data, the authors report improvements in some subjects using AHP-3 and PPP-4, with PPP-4 associated with larger measured changes than AHP-3 based on the data, photos, and self-assessment questionnaires. The authors describe this as an initial study supporting further research with larger sample sizes and longer duration.
Abstract
Crow's feet is one of the signs of skin aging. Many studies regarding skin aging have been carried out in Caucasians, as for Asians, there are different genotypes and phenotypes. Some anti-aging treatments carry a slightly higher risk of side effects and irritation in Asian skin. Currently, the use of topical active peptides for anti-aging, Acetylhexapeptide-3 (AHP-3) and Palmitoyl pentapeptide-4 (PPP-4), has been widely developed. This study aimed to investigate the anti-aging effects of AHP-3 and PPP-4 on the Asian patient with crow's feet. This study was a double-blind randomized trial using 21 Indonesian female subjects aged 26 to 55 years for eight weeks and divided into three groups: AHP-3 cream, PPP-4 cream, and placebo. The cream was applied twice daily to the periorbital area. The three groups were assessed using Corneometer, Tewameter, Cutometer, digital photography and Crow's Feet Grading Scale. Based on clinical photos and data, improvements were found in several subjects using AHP-3 and PPP-4. PPP-4 appeared to demonstrate better results when compared to AHP-3 based on data, clinical photos, and self-assessment questionnaire. PPP-4 demonstrated better results when compared to AHP-3 and placebo. This initial study provides an opportunity for further study with a more adequate number of samples and duration.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.